Deborah Davis

Professor

University of Louisville
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Year:

2026

Year:

2026

Background Current methods to quantify blood biomarkers for Alzheimer's disease (AD) are expensive and are not widely available. Objective To develop a low-cost, sensitive, and accurate multiplex assay to quantify Aβ 40 , Aβ 42 , p181Tau, p217Tau, NfL, and GFAP biomarkers in plasma and serum based on a widely available technology. Methods We used commercial antibodies to Aβ 40 , Aβ 42 , p181Tau, p217Tau, NfL, and GFAP, and xMAP Luminex technology, and developed the multiplex 5ADCSI to quantify these biomarkers from plasma and serum. The utility of 5ADCSI was tested in matched cerebrospinal fluid (CSF) and plasma or serum of a cohort of cognitively normal (CN: n = 35), with mild cognitive impairment (MCI: n = 17), and with AD (n = 11) individuals. Results The 5ADCSI demonstrated high specificity and sensitivity, with excellent precision. In clinical samples, moderate to strong correlation is observed between CSF and plasma or serum for Aβ 42/40 ( r = 0.78 ), p181Tau/Aβ 42 ( r = 0.57 ), p217Tau/Aβ 42 ( r = 0.72 ), p181Tau ( r = 0.59 ), p217Tau ( r = 0.75 ), and GFAP ( r = 0.59 ). The AUC of receiver-operator characteristic curve for differentiating CN from AD for plasma/serum and CSF are 0.75, and 0.80 for Aβ 42/40 , 0.95, 0.91 for p217Tau, 0.76, 0.81 for p181Tau, and 0.73 and 0.78for GFAP, respectively. Conclusions The 5ADCSI assay is highly specific, sensitive, and accurate. The wide availability of the base technology of 5ADCSI is an advantage over other similar methods and would allow cost-effective large-scale studies for validation of blood biomarkers for early diagnosis of AD.

Year:

2025

Rational use of psychotropic medications in youth This article examines a holistic approach to youth mental health care and discusses the concept of ‘deprescribing’ as a systematic method for assessing the necessity and risks associated with the continued use of medication. Systems models have long been considered when trying to understand individual differences in child health and development. (1-4) Within these models, it is posited that child outcomes are produced through complex dynamic interactions between the child’s biological characteristics and multiple levels of environmental influences. For example, immediate environments (microsystems) consist of family, peers, teachers, and neighborhoods, whereas more distal influences such as cultural values, beliefs, laws, and customs (macrosystems) provide a broader context within which the child and family live. (2) Other levels include mesosystems, ecosystems, and chronosystems. (2) This is important when thinking about childhood mental health. These complex system interactions must be considered when diagnosing and treating childhood mental health disorders because adverse environmental conditions have been associated with adverse mental health outcomes. Similarly, positive environmental interactions may have a protective influence on outcomes.

Year:

2025

Challenges in diagnosing and treating ADHD Professor Deborah Winders Davis from the University of Louisville School of Medicine outlines the challenges in diagnosing and treating attention deficit hyperactivity disorder. Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed disorders in childhood in the United States. (1,2) Approximately 11% of US children aged three to 17 years have ever had the diagnosis; (1) rates in the UK are less than half that. True, worldwide prevalence is difficult to determine due to gaps in data collection for various reasons. (3) Some reasons for variations in diagnosis may include provider bias, parental fears of being stigmatized, leading to under-reporting or not seeking help, differences in educational policies and practices, and increased risks associated with environmental factors, to name a few. There are risks associated with both under-diagnosing and over-diagnosing. Additionally, there are risks associated with treatment types.

Year:

2025

Background and Objectives: Racial and ethnic variations in antibiotic utilization are well-reported in outpatient settings but little is known about inpatient settings. Our objective was to describe national inpatient antibiotic utilization among children by race and ethnicity. Methods: This study included hospital visit data from the Pediatric Health Information System between 01/01/2022 and 12/31/2022 for patients <20 years. Primary outcomes were the percentage of hospitalization encounters that received an antibiotic and antibiotic days of therapy (DOT) per 1000 patient days. Mixed-effect regression models were used to determine the association of race-ethnicity with outcomes, adjusting for covariates. Results: There were 846,530 hospitalizations. 45.2% of children were Non-Hispanic (NH) White, 27.1% were Hispanic, 19.2% were NH Black, 4.5% were NH Other, 3.5% were NH Asian, 0.3% were NH Native Hawaiian/Other Pacific Islander (NHPI) and 0.2% were NH American Indian. Adjusting for covariates, NH Black children had lower odds of receiving antibiotics compared to NH White children (aOR 0.96, 95%CI 0.94–0.97), while NH NHPI had higher odds of receiving antibiotics (aOR 1.16, 95%CI 1.05–1.29). Children who were Hispanic, NH Asian, NH American Indian, and children who were NH Other received antibiotic DOT compared to NH White children, while NH NHPI children received more antibiotic DOT. Conclusions: Antibiotic utilization in children’s hospitals differs by race and ethnicity. Hospitals should assess policies and practices that may contribute to disparities in treatment; antibiotic stewardship programs may play an important role in promoting inpatient pharmacoequity. Additional research is needed to examine individual diagnoses, clinical outcomes, and drivers of variation.

Year:

2025

Objectives: Birth weight is a widely used indicator of prenatal experiences in models of the developmental origins of cognitive ability across the lifespan. Methods: We modeled change in the strength of the association between birth weight and cognitive ability in a sample of twins (n = 1,501; 53.1% female; 91.1% White) followed prospectively from infancy to midlife. Results: The magnitude of the association between birth weight and cognitive ability declined exponentially from infancy (β = .59, p < .05) to midlife (β = .27, p < .05). A 1-kilogram increase in birth weight was associated with an 8.85-point increase in cognitive scores at 3 months and a 4.05-point advantage after about 2.5 years. Biometric regression models revealed that shared environmental factors accounted for the decline in the association between birth weight and cognitive ability. A small, positive within-pair association persisted into midlife. Discussion: Findings support developmental origin models of cognitive ability across the lifespan.

Year:

2025

The conceptual and symptom overlap between depression and loneliness is so strong that depressive symptom rating scales often include measures of loneliness and their linear association ranges between .40 and .68. Despite these findings, few genetically informed studies have investigated the genetic and environmental association between them. In this brief report, we used 416 individual twins, 229 MZ twins and 187 DZ twins, from the Louisville Twin Study (MAge = 48.17; 56% female) to test two hypotheses: first, depressive symptomatology and loneliness are correlated genetically and environmentally; and second, the genetic correlation in women would be larger than men. Results from a correlated ACE factors model indicate that the genetic correlation is .52 and the nonshared environmental correlation is .27. No sex differences were observed. The strong genetic overlap between depressive symptomatology and loneliness raises questions about the biological mechanisms associated with common sets of genes.

Year:

2025

For decades, researchers have debated whether the magnitude of the Flynn Effect—intergenerational increases in mean IQ scores—varies across cognitive domains and subdomains, and whether the Flynn Effect reflects gains in general cognitive ability (g). We conducted a cross-domain, subtest-level investigation of the Flynn Effect across middle childhood and early adolescence (ages 7-15 years, N = 1187, 89% White, 9% Black, 52% female) in longitudinal cognitive ability data collected prospectively between 1957 and 1999 using three versions of the Wechsler Intelligence Scale for Children. Results provided clear evidence of the Flynn Effect as both increases in mean IQ score across generational cohort and decreases in mean IQ across test versions. Flynn Effect magnitude differed substantially across domains and subtests. Performance IQ gains were larger than full-scale and verbal IQ gains in cohort-based analyses, but test version-based estimates showed an opposite pattern (VIQ > FSIQ > PIQ). Variance in Flynn Effect magnitude across subtests did not follow a discernible pattern. The strength of the Flynn Effect on individual subtests was not strictly proportional to each subtest’s g-loading, with performance IQ subtests showing larger increases than would be expected given their g-loadings and verbal subtests showing smaller-than-expected gains.

Year:

2025

The heritability (G) of cognitive ability increases substantially across development. However, previous studies of G x Age interaction—also known as the Wilson Effect—have not controlled for developmental changes in the reliability of cognitive assessment. Unmodeled reliability changes may bias estimates of cognitive growth and G x Age interaction, obscuring the developmental etiology of cognitive ability, but this possibility has not been explored empirically due to a lack of appropriate data and statistical methods. Using an expanded version of the Louisville Twin Study data set in which Ronald Wilson (1983) originally documented G x Age interaction, we first replicated heritability increases between ages 3 months and 15 years. Then, we examined the extent to which unmodeled reliability changes biased estimates of G x Age interaction using continuous time dynamic modeling. Our-best fitting model, which corrected for reliability differences across test battery and age, estimated that heritability increased from .26 to .55. Reliability increased substantially across development, from less than .30 in infancy to approximately .80 at age 15. Models that did not control for developmental reliability increases yielded downwardly biased estimates of cognitive growth and differentiation, G x Age interaction, developmental decreases in shared environmental effects, and increases in non-shared environmental effects. Results indicated that a re-evaluation of previous G x Age estimates may be warranted, and that future studies should control for developmental fluctuations in reliability. Our continuous time dynamic models improved estimation of developmental change in cognitive ability and can be easily adapted to other psychological constructs.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (5)

Yana Feygin

Assistant Professor, Research Title Series

University of Kentucky

UNITED STATES
View details

Christopher Beam

Associate Professor

University of Southern California

UNITED STATES
View details

Evan Giangrande

Assistant Professor

University of South Carolina

UNITED STATES
View details

Jennifer Le

University of Louisville School of Medicine

UNITED STATES
View details

Charles C. Driver

University of Zurich

SWITZERLAND
View details